NLRP3 and acute kidney injury: This discrepancy may be due to Anc80L65 specifically targeting the kidney mesenchymal cell lineage, without affecting the macrophages recruited to the kidney during the progression of AKI.50 Altogether, A20 is potential therapeutic target for attenuating cisplatin-induced AKI through its regulation of the self-DNA-mediated STING pathway and NLRP3-driven pyroptosis.